![]() |
| Human colorectal cancer cells Image Credit: National Cancer Institute |
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) in cooperation with Saarland University. For its new study, published in the scientific journal Molecular Cancer, the team analyzed more than 140 tissue samples from bowel cancer patients and found there was a link between the concentration of IGF2BP2 and the characteristics of the tumors. The findings could help to develop better diagnostic procedures and possibly new forms of therapy in the future.
According to the Robert Koch Institute, bowel cancer is one of the most common cancers in Germany. In 2019, 58,967 men and women were diagnosed with it. "If caught early, bowel cancer can be removed quite well by surgery and it is therefore often curable," says the leader of the study, Professor Sonja Kessler from the Institute of Pharmacy at MLU. Once the disease has progressed, surgery is often no longer an option. In some cases, tumors can develop resistance to common forms of chemotherapy, which means they no longer respond to treatment. "We still do not know how and why some tumors develop this resistance. Currently, there are no reliable tests that can predict this at an early stage," Kessler adds.






.jpg)
.jpg)





.jpg)
